Healthcare News

BioNTech stärkt strategische Ausrichtung auf die wachsende spätklinische Pipeline mit Immunmodulator-, Antikörper-Wirkstoff-Konjugat- und mRNA-Kandidaten BioNTech-Mitgründer Ugur Sahin und Özlem...

BioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidatesBioNTech co-founders Ugur Sahin and Özlem Türeci will...

BPL‑003 holds Breakthrough Therapy Designation and is supported by positive Phase 2b results in treatment-resistant depressionCash runway reaffirmed through the planned early-2029 topline readouts...

PORTLAND, Ore., March 10, 2026 (GLOBE NEWSWIRE) -- EVAA.AI, part of the MaximEyes AI suite by First Insight, announced today at Vision Expo 2026 (Booth 2317) a major expansion of its AI-powered...

Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy1 Teclistamab monotherapy delivered superior progression-free...

GLASGOW, United Kingdom, March 10, 2026 (GLOBE NEWSWIRE) -- EnteroBiotix, a clinical-stage biopharmaceutical company developing best-in-class microbiome therapies, today announced that the...

Kainova Therapeutics announces positive Phase I results for DT‑9081, showing strong safety, target engagement and early anti‑tumor activity.

PRESS RELEASE  10/03/2025, 08:00 CET Biocartis Receives European IVDR Certification for the Idylla™ CDx MSI Test Idylla™ CDx MSI Test is the Second Fully Automated Companion Diagnostic Test Approval...

Nantes, France, 10 mars 2026 – 7h30 CET – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE) annonce aujourd’hui la transition de Marc Le Bozec de Directeur Général par intérim à Directeur...

OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth